Chest
Original ResearchLymphangioleiomyomatosisSerum Vascular Endothelial Growth Factor-D Prospectively Distinguishes Lymphangioleiomyomatosis From Other Diseases
Section snippets
Study Population
Prospective VEGF-D testing was performed in 48 women presenting for clinical evaluation who did not meet criteria for definite LAM diagnosis at the time of initial evaluation. In comparison, results of retrospectively performed VEGF-D testing were analyzed from 122 women with known diagnoses. Subjects were recruited from pulmonary clinics and LAM and TSC clinics at the University of Cincinnati and Cincinnati Children's Hospital Medical Center, and via referral from other physicians and several
Study Subjects
Serum samples were evaluated from 195 female subjects with definite S-LAM or other proven causes of cystic lung disease that may mimic LAM (emphysema, PLCH, BHD, and Sjögren), TSC-LAM, TSC only, lymphangiomatosis, and healthy volunteers. The clinical characteristics of the study population are shown in Table 1. The presentations and disease severity of subjects with LAM and those with other cystic lung diseases were similar. There was no significant difference in the age of subjects with LAM
Discussion
The objective of this study was to prospectively evaluate the test characteristics and diagnostic usefulness of serum VEGF-D for LAM. We found that VEGF-D effectively discriminated LAM and lone elevated serum LAM from other cystic lung diseases that are commonly considered in the differential diagnosis, and was associated with the presence of cystic lung disease in women with TSC. We conclude that serum VEGF-D is a useful diagnostic test for S-LAM and a promising screening tool for LAM in women
References (21)
Lymphangioleiomyomatosis: a clinical update
Chest
(2008)- et al.
Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2
Am J Hum Genet
(2001) - et al.
Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement
Chest
(2009) - et al.
Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium
Am J Pathol
(2009) - et al.
Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans
Am J Respir Cell Mol Biol
(2007) Lymphangioleiomyomatosis
Eur Respir J
(2006)- et al.
Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis
Am J Respir Crit Care Med
(2001) - et al.
Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex
Am J Respir Crit Care Med
(2001) - et al.
The tuberous sclerosis complex
N Engl J Med
(2006) - et al.
The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment
Am J Respir Crit Care Med
(2006)
Cited by (0)
Funding/Support: This study was funded in part by a pilot project grant from The LAM Foundation, The Tante Mela Foundation, and NIH/NHLBI RR19498. This research was also supported in part by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research. This project has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E (to L. S. S.).
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).